


◆ August 2015: Highlights

- Amid seasonal slowdown in deal flow, **IPOX Indexes** join market to record significant losses.
- **Indexes** recede some of the YTD outperformance.
- More IPOX-linked index funds launch in the world regions.

[August 2015]

Amid seasonal slowdown in deal flow, **IPOX Indexes** join market to record significant losses. On the global level, the key USD trillion 1.4 **IPOX Global 50** (IPGL50) suffered its worst decline since 05/2012, shedding -7.78% to +0.30% YTD, slightly lagging



the benchmarks. The weakness was broad-based with the **IPOX Regional Indexes** also recording significant declines. Global IPO deal flow was seasonally subdued, however, produced some notable select deals. Demand continued to be solid for the mostly mid-cap focused IPOs in specialty industries linked to U.S. biotech and the U.S. consumer with firms including **Aimmune Therapeutics** (AIMT US), **Amplify Snack Brands** (BETR US), **Global Blood Therapeutics** (GBT US), **Houlihan Lokey** (HLI US), **Planet Fitness** (PLNT US) or **Sunrun** (RUN US) in U.S. focus, and the H-share offering of **China Railway Signal & Communications** (3969 HK) being the only significant IPO taking place outside the U.S. Amid the spike in volatility, initial trading statistics underline the divergence of interest, with the average (median) equally-weighted IPO gaining +19.96% (+0.32%) based on the difference between the final offering price and the first close.


Indexes recede some of the YTD outperformance. In the cross-section, the big decline in the **IPOX Global 50** (IPGL50) extended to the **IPOX Regional Indexes** universe. For example, the **IPOX Europe** (IXTE) fell -6.31% to +16.64% YTD, while the **IPOX U.S. 100** (IPXO) shed -7.67% to +2.72%YTD, still substantially outpacing the respective benchmarks YTD. The indexes counted the slew of high-beta specialty IPOs as recording the largest losses, including U.S. synthetic biology services provider Bill Miller pick **Intrexon** (XON US: -31.80%), health care firm Spin-off **Mallinckrodt** (MNK US: -30.43%), German tech incubator **Rocket Internet** (RKEY GY: -23.39%),

IPOX Returns (%) (Price)	08/15	2014	YTD 15
Exposure: Global/International (xUS) (USD)			
IPOX Global 50 (IPGL50)	-7.78	1.18	0.30
IPOX International (IPXI)*	-8.34	-4.81	-6.75
Exposure: United States (USD)			
IPOX U.S. 100 (IPXO)*	-7.67	11.02	2.72
IPOX U.S. 30 (IPXT)	-6.70	14.59	4.50
Exposure: Europe (EUR)			
IPOX Europe (IXTE)	-6.31	9.15	16.64
IPOX Nordic (IPND)	-5.88	7.97	14.16
Exposure: Asia-Pacific (Developed) (USD)			
IPOX Asia-Pacific 30 (IPTA)	-6.24	-5.37	-1.61
Exposure: China (USD) (x A-Shares)			
IPOX China 20 (CNI)	-14.09	3.08	-15.05

*Basis for Exchange-Traded Products (ETPs)

H.K.-traded Financial **CITIC Securities** (6030 HK: -26.70%) or **WH Group** (288 HK: -18.11%), the world's largest pork producer. Portfolio holdings with notable gains during the month included beauty products maker **Coty** (COTY US: +13.39%), IL-based drug maker Spin-off **Baxalta** (BXL US: +7.07%), Australia's private health care insurance provider **Medibank** (MPL AT: +11.48%), Chinese dairy producer **China Huishan** (6863 HK: +20.85%) or French application software maker **Worldline** (WLN FP: +3.98%).

IPOX® U.S-Style Investing since 2010:



More IPOX-linked index funds launch in the world regions. IPOX Schuster LLC is pleased to note the launch of the **First Trust US IPO Index UCITS ETF** (FPX LN, FPXU FP) which extends trading access to the **IPOX U.S. 100** (IPXO) beyond the U.S. trading hours to European investors. The fund is listed on the London Stock Exchange and Euronext Paris.